PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors

17-Jun-2013 - United Kingdom

The European Medicines Agency’s pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the effects of the painkiller diclofenac on the heart and circulation when given systemically (by means such as capsules, tablets or injections) are similar to those of selective COX-2 inhibitors, another group of painkillers. This applies particularly when diclofenac is used at a high dose (150 mg daily) and for long-term treatment. The PRAC concluded that the benefits of diclofenac still outweigh the risks but recommended that the precautions already in place to minimise the risks of arterial thromboembolic events (blood clots in the arteries) with selective COX-2 inhibitors should also be applied to diclofenac.

Patients who have serious underlying heart or circulatory conditions, such as heart failure, heart disease, circulatory problems or a previous heart attack or stroke, should not use diclofenac. Patients with certain cardiovascular risk factors (such as high blood pressure, raised blood cholesterol, diabetes or smoking) should only use diclofenac after careful consideration. Healthcare professionals will also be advised to periodically re-assess the need for patients to continue taking the medicine.

Diclofenac is a widely used medicine for relieving pain and inflammation, particularly in painful conditions such as arthritis. It belongs to a group of medicines called ‘non-steroidal anti-inflammatory drugs’ (NSAIDs). The selective COX-2 inhibitors are a subgroup of the NSAIDs.

The safety of NSAIDs has been closely monitored by regulatory authorities in the European Union. Reviews of these medicines carried out in 2005, 2006 and 2012 have confirmed that NSAIDs as a class are associated with a small increased risk of arterial thromboembolic events, which in some cases has led to heart attack or stroke, particularly if used at high dose and for long-term treatment.

The product information for all NSAIDs warns of this risk, and recommends that NSAIDs be used at the lowest effective dose for the shortest period of time necessary to control symptoms.

The PRAC review of diclofenac was started in October 2012 in response to findings from the 2012 review of NSAIDs, which identified a small increased risk of these cardiovascular side effects with diclofenac compared with other NSAIDs - an increase similar to that seen with the COX-2 inhibitors. The absolute cardiovascular risk with any NSAID depends on a person’s underlying risk factors, such as high blood pressure and cholesterol levels. For diclofenac, the overall number of heart attacks would be expected to increase by approximately 3 cases per year for every 1,000 people at moderate risk treated (from 8 per 1,000 people per year normally, to 11 per 1,000 people per year taking the medicine).

Generating best evidence to address regulatory research needs

The availability of robust evidence generated by independent academic research has been a central element of the reviews of NSAIDs and diclofenac. This includes an independent research project called ‘safety of non-steroidal anti-inflammatory drugs’ (SOS)², set up and funded by the European Commission’s Seventh Framework Programme to address questions identified in the 2006 review of NSAIDs, which provided data reviewed in 2012. Other groups have also been investigating the cardiovascular safety of NSAIDs, notably the Coxib and traditional NSAID Trialists' (CNT) collaborative group¹, who shared their results from a large meta-analysis of more than 600 randomised clinical trials with the Agency.

Other news from the department politics & laws

More news from our other portals

All FT-IR spectrometer manufacturers at a glance